Current Editions
70% of new precision medicines approved by FDA in past three years were not sponsored by major pharmas
Product Development
An upcoming eligibility expansion a gene editing opportunity, but leaves AAVs in the dark
Product Development
Itm and Perspective’s readouts are the latest clinical advances in GEP-NETs, the first indication to put radioligand therapies on the map
Product Development
Current, former agency staff say personnel losses from plans to slash government payrolls threaten short- and long-term harm
Politics, Policy & Law
Draft order would halve FDA staff, cut NIH, eliminate CDC, sources tell BioCentury
Politics, Policy & Law
Product Development
CEO of Foresite Labs betting on integrating AI/MI with medical product R&D — The BioCentury Show
Aims to drive additional weight loss after analysis of Phase III REDEFINE 1 obesity data
Emerging Company Profile
N.J.-based company uses metabolites in hair strands to track biological responses to environmental exposures over time
Editor's Commentary
Pfizer’s drop of a late-stage ADC this week may signal the ADC frenzy is cooling
Guest Commentary
There is an assault on the foundation of U.S. science: Silence is not an option
Regulatory agency must be proactive in fighting the surge in skepticism about the drugs and vaccines it regulates
Market Access
Iqvia’s latest report cites regulatory requirements, investment costs, and lack of market acceptance and predictability
Discovery & Translation
BioCentury’s roundup of translational innovations also includes new insight into repeat expansion in Huntington’s and 10 new products
BioCentury’s roundup of translational innovation also includes high-resolution spatial proteomics, a more diverse microbiome atlas, and more
Deals
Japanese pharma’s parent chooses $3.4B buyout to create PE-backed standalone company
Finance
German biotech Akribion advancing nucleases for programmable cell depletion; Finland’s Aplagon developing vascular treatment
Vertex competitor posts a first-day gain after an upsized offering; plus financings for Gh Research and Tectonic
Expanding in U.S., the biotech will build manufacturing capacity for α-emitters, including clinical program for prostate cancer
Management Tracks
The non-profit launches to overcome C-suite underrepresentation by helping U.S. biopharma leaders of East Asian descent advance in their careers
Biopharma Stock Performers
Use BioCentury's interactive dashboard to view top-performing biopharma stocks for the day and the week.
Product Development
Politics, Policy & Law
Management Tracks
BioCentury ISSN 1097-7201